PharmaShots | Incisive News in 3 Shots

Subscribe Now

Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Reports the US FDA's Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA

Omeros Reports the US FDA's Acceptance and Priority Review of BLA for Narsoplimab (OMS721) to Treat HSCT-TMA

January 20, 2021

Omeros' OMS721 Receives FDA's ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros' OMS721 Receives FDA's ODD to Treat Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

October 24, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us